Navigation Links
GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
Date:3/15/2012

ous diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec President and Chief Executive Officer Announces Retirement
2. GenVec Achieves Second Milestone in Collaboration
3. GenVec to Present at the 2011 10th Annual BIO Investor Forum
4. GenVec Renews Stockholder Rights Plan
5. GenVec Reports First Quarter 2011 Financial Results
6. GenVec Regains Compliance with NASDAQ Listing Requirements
7. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
8. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
11. GenVec Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 This is a ... and China Isopropanol (IPA) industry. The report provides ... applications and industry chain structure. Global market analysis ... a focus on history, developments, trends and competitive ... international and Chinese situation is also offered. , ...
(Date:9/23/2014)... New York , September 23, 2014 /PRNewswire/ ... a leading provider of  Closed System Transfer     ... new exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation. ... bodies in Taiwan , ... approval as the company continues to expand globally, ...
(Date:9/23/2014)... Greenville, SC (PRWEB) September 23, 2014 ... ) my third book on healthcare offers a three ... a 21st century healthcare delivery system that would go ... each state’s responsibility regarding the delivery of healthcare.” , ... patient safety has failed to provide discernable progress throughout ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
Breaking Biology Technology:(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... has received FDA clearance for the,marketing of the ATS 3f(R) ... an improved valve holder accessory device. , ... While the ATS 3f Aortic ...
... Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th ... be presented by Dr Thomas Bumm of Oregon Health and Sciences ... model of myeloproliferative disorders. , , Full ... CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induc e ...
... http://www.yourwaytransport.com ), a premium global courier that provides,customized ... biotechnology and medical/healthcare industries, today,announced that it is ... The,expansion includes a new, larger facility, enhanced web ... The company has relocated ...
Cached Biology Technology:ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3Yourway Transport Expands 2
(Date:9/23/2014)... gotten a lot greener thanks to a novel technique ... uses solar energy to accelerate tailings pond reclamation efforts ... a light source to treat oil sands process affected ... El-Din and James Bolton have found that using the ... just as efficiently but at a much lower cost. ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... soils store four times more carbon than the ... can have a big effect on atmospheric greenhouse ... Nature Climate Change concludes that climate ... or affect soil carbon storage, despite increases in ... U.S. Forest Service Research Ecologist Dr. Christian Giardina, ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Study helps assess impact of temperature on belowground soil decomposition 2
... Zoo-based Wildlife Conservation Society (WCS) warn that efforts to ... beyond must focus on better management practices on farms ... Mongolian agencies on the ground in Mongolia's Kovsgol province, ... the virus. , "We're working with our Mongolian and ...
... anyone with respiratory problems, air pollution can significantly impair ... satellites and stations on the ground to develop a ... quality forecasts. , Understanding how tropospheric or near-surface-level ozone ... region to region and continent to continent is an ...
... may have a surprisingly close-to-home answer, according to one University ... is important in obtaining clues as to where else in ... be like, said George E. Fox, a UH professor of ... research grant from NASA's Exobiology Program that seeks to understand ...
Cached Biology News:WCS says avian flu prevention should focus on farms, markets 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 3Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: